[go: up one dir, main page]

DK1274430T3 - Cabergolin til behandling af fibromyalgi og kronisk trathedssyndrom - Google Patents

Cabergolin til behandling af fibromyalgi og kronisk trathedssyndrom

Info

Publication number
DK1274430T3
DK1274430T3 DK01926590T DK01926590T DK1274430T3 DK 1274430 T3 DK1274430 T3 DK 1274430T3 DK 01926590 T DK01926590 T DK 01926590T DK 01926590 T DK01926590 T DK 01926590T DK 1274430 T3 DK1274430 T3 DK 1274430T3
Authority
DK
Denmark
Prior art keywords
cabergoline
fibromyalgia
treatment
chronic fatigue
fatigue syndrome
Prior art date
Application number
DK01926590T
Other languages
Danish (da)
English (en)
Inventor
Robert B Mccall
Robert C Marshall
David W Robertson
Thomas M Ashley
Original Assignee
Pharmacia & Upjohn Co Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia & Upjohn Co Llc filed Critical Pharmacia & Upjohn Co Llc
Application granted granted Critical
Publication of DK1274430T3 publication Critical patent/DK1274430T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/451Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4738Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/48Ergoline derivatives, e.g. lysergic acid, ergotamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)
DK01926590T 2000-04-21 2001-04-17 Cabergolin til behandling af fibromyalgi og kronisk trathedssyndrom DK1274430T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19895900P 2000-04-21 2000-04-21
US20056900P 2000-04-28 2000-04-28

Publications (1)

Publication Number Publication Date
DK1274430T3 true DK1274430T3 (da) 2006-02-13

Family

ID=26894316

Family Applications (1)

Application Number Title Priority Date Filing Date
DK01926590T DK1274430T3 (da) 2000-04-21 2001-04-17 Cabergolin til behandling af fibromyalgi og kronisk trathedssyndrom

Country Status (16)

Country Link
US (3) US6448258B2 (es)
EP (1) EP1274430B1 (es)
JP (1) JP2004502650A (es)
KR (1) KR20040007215A (es)
CN (3) CN1554341A (es)
AR (3) AR028355A1 (es)
AT (1) ATE312608T1 (es)
AU (2) AU2001253114B2 (es)
BR (1) BR0110210A (es)
CA (1) CA2405565A1 (es)
DE (1) DE60115872T2 (es)
DK (1) DK1274430T3 (es)
ES (1) ES2253370T3 (es)
NZ (3) NZ531171A (es)
PE (1) PE20011212A1 (es)
WO (1) WO2001081343A2 (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE46117E1 (en) 1999-12-22 2016-08-23 Teva Pharmaceuticals International Gmbh Modulators of dopamine neurotransmission
BR0110188A (pt) * 2000-04-21 2003-03-05 Upjohn Co Compostos selecionados para o tratamento de sìndromes de fibromialgia e de fadiga crÈnica
AR033520A1 (es) * 2000-04-27 2003-12-26 Upjohn Co (5r)-(metilamino) -5,6-dihidro-4h-imidazo[4,5,1-ij] quinolin-2(1h)-tiona
WO2002013807A2 (en) * 2000-08-16 2002-02-21 Pharmacia & Upjohn Company Compounds for the treatment of addictive disorders
DE10041478A1 (de) 2000-08-24 2002-03-14 Sanol Arznei Schwarz Gmbh Neue pharmazeutische Zusammensetzung
AR031152A1 (es) * 2000-10-31 2003-09-10 Upjohn Co Tratamientos nuevos para el sindrome de piernas inquietas
EP1546120A4 (en) * 2002-10-04 2006-11-22 Pharmacia Corp PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF PARKINSON'S DISEASE
CA2500919A1 (en) * 2002-10-04 2004-04-22 Pharmacia Corporation Compositions and methods for treating sexual dysfunction
CN101263136A (zh) 2005-07-13 2008-09-10 弗·哈夫曼-拉罗切有限公司 作为5-ht6、5-ht24的苯并咪唑衍生物
TWI392670B (zh) * 2006-06-22 2013-04-11 Ucb Pharma Gmbh 經取代的2-胺基萘滿之於製造用於預防、減緩及/或治療各種類型疼痛之藥物上的用途
ES2332645B1 (es) * 2009-06-30 2010-10-18 Grifols, S.A. Utilizacion de alfa-1-antitripsina para la preparacion de medicamentos para el tratamiento del sindrome de fatiga cronica.
DK2618826T3 (en) * 2010-09-20 2016-08-01 A Carlsson Res Ab Phenylpiperdine FOR TREATMENT OF DEMENTIA
MX366703B (es) 2013-03-15 2019-07-22 Incyte Holdings Corp Heterociclos tricíclicos como inhibidores de la proteína bet.
EP3019502B1 (en) 2013-07-08 2017-05-17 Incyte Holdings Corporation Tricyclic heterocycles as bet protein inhibitors
WO2015081189A1 (en) 2013-11-26 2015-06-04 Incyte Corporation Bicyclic heterocycles as bet protein inhibitors
US9399640B2 (en) 2013-11-26 2016-07-26 Incyte Corporation Substituted pyrrolo[2,3-c]pyridines and pyrazolo[3,4-c]pyridines as BET protein inhibitors
WO2015095492A1 (en) 2013-12-19 2015-06-25 Incyte Corporation Tricyclic heterocycles as bet protein inhibitors
KR102702503B1 (ko) 2014-04-23 2024-09-05 인사이트 홀딩스 코포레이션 BET 단백질의 저해제로서의 1H-피롤로[2,3-c]피리딘-7(6H)-온 및 피라졸로[3,4-c]피리딘-7(6H)-온
DE102014008742A1 (de) * 2014-06-12 2015-12-17 Daimler Ag Separator für einen elektrochemischen Speicher, Verfahren zur Herstellung eines Elektrodenmaterials sowie elektrochemischer Energiespeicher
WO2016044130A1 (en) 2014-09-15 2016-03-24 Incyte Corporation Tricyclic heterocycles for use as bet protein inhibitors
WO2016180879A1 (en) * 2015-05-13 2016-11-17 A. Carlsson Research Ab Treatment of debilitating fatigue
US20170121347A1 (en) 2015-10-29 2017-05-04 Incyte Corporation Amorphous solid form of a bet protein inhibitor
PH12021551886A1 (en) 2016-06-20 2023-07-17 Incyte Corp Crystalline solid forms of a bet inhibitor
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4526892A (en) * 1981-03-03 1985-07-02 Farmitalia Carlo Erba, S.P.A. Dimethylaminoalkyl-3-(ergoline-8'βcarbonyl)-ureas
KR0167346B1 (ko) * 1989-06-09 1999-01-15 로버트 에이. 아미테이지 중추신경계 활성을 갖는 헤테로사이클릭 아민
US5273975A (en) 1989-06-09 1993-12-28 The Upjohn Company Heterocyclic amines having central nervous system activity
CA2105666C (en) 1991-04-17 2006-02-14 Kjell Anders Ivan Svensson New centrally acting substituted phenylazacycloalkanes
KR100335548B1 (ko) 1993-07-27 2002-10-04 파마시아 앤드 업존 캄파니 중추신경계활성을갖는헤테로사이클아민
JPH1053525A (ja) * 1996-06-06 1998-02-24 Bitakain Seiyaku Kk 疼痛治療剤
US6455564B1 (en) 1999-01-06 2002-09-24 Pharmacia & Upjohn Company Method of treating sexual disturbances
AU3490300A (en) * 1999-03-12 2000-10-04 Nitromed, Inc. Dopamine agonists in combination with nitric oxide donors, compositions and methods of use
ES2247572T3 (es) * 1999-07-01 2006-03-01 PHARMACIA & UPJOHN COMPANY LLC (s,s)-reboxetina para tratar las cefaleas migrañosas.
DE19938823A1 (de) 1999-08-19 2001-02-22 Boehringer Ingelheim Pharma Medikamentöse Behandlung des Restless Leg Syndroms
AU6917400A (en) * 1999-08-31 2001-03-26 Alcon Laboratories, Inc. Use of 5-ht1b/1d agonists to treat otic pain

Also Published As

Publication number Publication date
EP1274430B1 (en) 2005-12-14
AU5311401A (en) 2001-11-07
CN1554343A (zh) 2004-12-15
CN1554341A (zh) 2004-12-15
DE60115872T2 (de) 2006-07-13
WO2001081343A2 (en) 2001-11-01
NZ531171A (en) 2005-03-24
US6555548B2 (en) 2003-04-29
WO2001081343A3 (en) 2002-02-28
ATE312608T1 (de) 2005-12-15
BR0110210A (pt) 2003-01-28
US20030191149A1 (en) 2003-10-09
ES2253370T3 (es) 2006-06-01
US20020004510A1 (en) 2002-01-10
CA2405565A1 (en) 2001-11-01
NZ522112A (en) 2004-10-29
NZ531172A (en) 2005-07-29
AR039632A2 (es) 2005-03-02
US6448258B2 (en) 2002-09-10
AR039633A2 (es) 2005-03-02
AR028355A1 (es) 2003-05-07
PE20011212A1 (es) 2001-11-21
EP1274430A2 (en) 2003-01-15
US20020143010A1 (en) 2002-10-03
KR20040007215A (ko) 2004-01-24
CN1450898A (zh) 2003-10-22
DE60115872D1 (de) 2006-01-19
JP2004502650A (ja) 2004-01-29
AU2001253114B2 (en) 2005-08-25

Similar Documents

Publication Publication Date Title
DK1274430T3 (da) Cabergolin til behandling af fibromyalgi og kronisk trathedssyndrom
NO20011964D0 (no) Brönnbehandlingsfluider og fremgangsmåter med anvendelse derav
FI20011421L (fi) Menetelmä ja laite toiminnon toteuttamiseksi
DK1632234T3 (da) (S,S)-reboxetin til behandling af kronisk træthedssyndrom
EP1412378A4 (en) APTAMERES AND ANTIAPTAMERS
ATE306318T1 (de) Entschwefelung und hierfür geeignetes sorbens
DE60207321D1 (de) Verschlussvorrichtung und -methode
NO20034159L (no) Östrogen-gestagen-kombinasjonspreparat og anvendelse derav
DE60220486D1 (de) Zurückschaltungseinrichtung und Zurückschaltungsverfahren
NO20033854L (no) N-but-3-enyl-norbuprenorfin og fremgangsmåter for anvendelse
DK1478438T3 (da) Fremgangsmåder og sammensætninger til behandling af astma
NO20052009D0 (no) Kombinasjonsterapi for behandling av akutt leukumi og myelodysplastikksyndrom
FI20012460L (fi) Putkiston haarakappale
DK1337547T3 (da) Nuklease-baseret fremgangsmåde til detektion og kvantificering af oligonukleotider
FI20011370A0 (fi) Biotunnistusmenetelmä ja sitä hyödyntävä laite
NO20010464L (no) FremgangsmÕter og preparater for behandling av gastro- øsofagealt-reflukssyndrom
DE60205700D1 (de) Fehlerkorrekturvorrichtung und -verfahren
DK0951289T3 (da) Anvendelse af Mycobacterium vaccae til behandling af kronisk træthedssyndrom
FI20010212L (fi) Menetelmä vertailuajan virheen määrittämiseksi ja elektroniikkalaite
DK1381620T3 (da) Hypersulfaterede disaccharider og fremgangsmåder til anvendelse af samme til behandling af inflammationer
ZA200208272B (en) Treatment of fibromyalgia and chronic fatigue syndrome.
DE50210561D1 (de) Sitz- und/oder liegemöbel
DK1017381T3 (da) Butyratderivater til behandling af fibromyalgi og kronisk træthedssyndrom
AU2002225881A1 (en) Treatment of chronic fatigue syndrome and fibromyalgia syndrome
SI1274430T1 (sl) Kabergolin za zdravljenje fibromialgije in sindroma kronicne utrujenosti